Skip to main content
NEO:HALO

Halozyme Therapeutics Stock Forecast, Price & News

C$43.40
+1.63 (+3.90 %)
(As of 05/14/2021 01:23 PM ET)
Add
Compare
Today's Range
C$41.69
C$43.43
50-Day Range N/A
52-Week Range
C$22.11
C$56.40
Volume10,050 shs
Average Volume1.32 million shs
Market CapitalizationC$6.18 billion
P/E Ratio47.69
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Halozyme Therapeutics

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone858 794 8889
Employees136
Year FoundedN/A

Sales & Book Value

Annual SalesC$267.59 million
Cash FlowC$2.48 per share
Book ValueC$1.12 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market CapC$6.18 billion
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

1.25 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Halozyme Therapeutics (NEO:HALO) Frequently Asked Questions

Is Halozyme Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Halozyme Therapeutics?

Wall Street analysts have given Halozyme Therapeutics a "Strong Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Halozyme Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for HALO?

1 equities research analysts have issued 12 month price targets for Halozyme Therapeutics' stock. Their forecasts range from C$0.24 to C$0.24. On average, they anticipate Halozyme Therapeutics' share price to reach C$0.24 in the next year. This suggests that the stock has a possible downside of 99.4%.
View analysts' price targets for Halozyme Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the following people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 58, Pay $1.52M)
  • Ms. Elaine D. Sun, Sr. VP & CFO (Age 49, Pay $859.58k)
  • Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 57, Pay $710.18k)
  • Mr. Masaru Matsuda Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50, Pay $707.84k)
  • Mr. Ed Gemo, VP, Chief Information & Security Officer
  • Mr. Albert S. Kildani, VP of Investor Relations & Corp. Communications
  • Ms. Amy Marinne Fox, VP of HR
  • Mr. William J. Fallon, Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances (Age 64)
  • Dr. Steve Knowles, Chief Medical Officer
  • Mr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project Management

Who are some of Halozyme Therapeutics' key competitors?

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the Canada's New Stock Exchange (NEO) under the ticker symbol "HALO."

How do I buy shares of Halozyme Therapeutics?

Shares of HALO and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately C$43.40.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics has a market capitalization of C$6.18 billion and generates C$267.59 million in revenue each year.

How many employees does Halozyme Therapeutics have?

Halozyme Therapeutics employs 136 workers across the globe.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

How can I contact Halozyme Therapeutics?

The company can be reached via phone at 858 794 8889.


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.